obesity drug news today glp-1 october 23 2025 New oral delivers up to 12% weight loss in 36 weeks How to Invest in GLP-1

Regulatory and Insurance Changes: The approval of the first oral GLP-1 (Dec 2025) with explicit labeling for obesity (and overweight with comorbidities) ( [25] ) ( [67] ) will likely broaden insurance coverage scenarios

Glucagon-Like Peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes

Frequent vomiting, persistent nausea, or inability to maintain normal food intake should always be evaluated

Medicare will cover Wegovy (semaglutide), Foundayo (orforglipron), and the KwikPen formulation of Zepbound (tirzepatide)

This may occur by direct activation of GLP-1R in skeletal muscle to increase mitochondrial biogenesis and antioxidant activity